Olema Pharmaceuticals, Inc. (OLMA) saw its stock price plummet by 5.01% during intraday trading on Wednesday.
The sharp decline followed news that Goldman Sachs analyst Richard Law significantly lowered the firm's price target on Olema Oncology to $27 from $38. While the analyst maintained a Buy rating on the shares, the substantial reduction in the price target represents a negative catalyst that likely contributed to the selling pressure.